Tenax Therapeutics is trading 12.97% up at $2.09 in after-hours trading, with no clear company-specific catalyst identified for August 24, 2026.
- The latest major development remains the August 10 Phase 3 LEVEL trial failure, which missed its primary endpoint and previously pressured shares.
- Available reporting does not directly link that failure to the rebound; the S&P 500 was lower while the Dow rose.
- Delayed filings or late-breaking announcements should be rechecked.